Werewolf Therapeutics
Filed with the SEC on · accession 0001193125-26-452789
HOWL filed a 8-K (current report) with the SEC on Nov 9, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The stock moved +0.0% by the first close after the filing.
Werewolf Therapeutics announced new clinical data from its Phase 1/1b trial of WTX-124 and Phase 1b/2 trial of WTX-330, its conditionally activated IL-2 and IL-12 INDUKINE molecules for solid tumors, via a press release furnished under Item 7.01.
Close before
$1.01
Nov 6, 2026
First close after
+0.00%
$1.01
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for HOWL, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for HOWL?
Click hereHOWL filed a 8-K (SEC filing). Werewolf Therapeutics announced new clinical data from its Phase 1/1b trial of WTX-124 and Phase 1b/2 trial of WTX-330, its conditionally activated IL-2 and IL-12 INDUKINE molecules for solid tumors, via a press release furnished under Item 7.01.
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
HOWL closed at $1.01 before the filing and $1.01 on Nov 9, 2026 (+0.00%).
Get alerts when HOWL files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days